Multimodal functional imaging investigation before and after the onset of psychosis

International Journal of Neuropsychopharmacology

Volumn 12, Issue 4, 2009, Pages 579-581

  Fusar Poli, Paolo ^a,b   Howes, Oliver ^b   Valli, Isabel ^b   Allen, Paul ^b   Broome, Matthew ^b   Grasby, Paul ^b,c   McGuire, Philip ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; ARIPIPRAZOLE; CARBIDOPA; CESIUM 137; DOPAMINE; ENTACAPONE; HALOPERIDOL; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; CASE REPORT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HALLUCINATION; HUMAN; LETTER; MALE; PARANOIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; VISUAL HALLUCINATION; BRAIN; DIAGNOSTIC IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANOID SCHIZOPHRENIA; PATHOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; SCINTISCANNING;

BRAIN; DIAGNOSTIC IMAGING; DIHYDROXYPHENYLALANINE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RADIOPHARMACEUTICALS; SCHIZOPHRENIA, PARANOID; YOUNG ADULT;

EID: 67649202844     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114570800953X     Document Type: Letter

References (14)

1. Cropley VL, Fujita M, Innis RB, Nathan PJ (2006). Molecular imaging of the dopaminergic system and its association with human cognitive function. Biological Psychiatry 59, 898-907.
2. Floresco SB, Magyar O (2006). Mesocortical dopamine modulation of executive functions: beyond working memory. Psychopharmacology 188, 567-585.
3. Fusar Poli P, Perez J, Broome M, Borgwardt S, Placentino A (2007). Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews 31, 465-484.
4. Grunder G, Vernaleken I, Muller MJ, Davids E, Heydari N, Buchholz HG (2003). Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 28, 787-794.
5. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Grasby P (in press). Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Archives of General Psychiatry.
6. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T (2006). Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry 163, 790-799.
7. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S (2002). Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry 59, 921-928.
8. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P (2004). Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Archives of General Psychiatry 61, 134-142.
9. McGuire P, Howes OD, Stone J, Fusar-Poli P (2008). Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends in Pharmacologi al Science 29,91-98.
10. Tanaka S (2006). Dopaminergic control of working memory and its relevance to schizophrenia: a circuit dynamics perspective. Neuroscience 139, 153-171.
11. Vernaleken I, Kumakura Y, Cumming P, Buchholz HG, Siessmeier T, Stoeter P (2006). Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. Neuroimage 30, 1332-1339.
12. Weinhard K (1998). The Theory and Practice of 3D PET. In: Bendriem B, Townsend DW (Eds), pp. 150-154. Dordrecht: Kluwer Academic Publishers.
13. Yung A, Phillips L, McGorry P, Ward J, Donovan K (2002). Comprehensive Assessment of At Risk Mental States (CAARMS). Melbourne: PACE Clinic, Department of Psychiatry, University of Melbourne.
14. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA (2003). Psychosis prediction: 12-month follow up of a high-risk ('prodromal') group. Schizophrenia Research 60, 21-32.